In a study on relapse rates of high-risk stage II and III colorectal cancers, the 2251A>C polymorphism of XPD (ERCC2) was significantly correlated with early relapse after chemotherapeutic treatment [199]. This evidence concerns the gene ERCC2 and colorectal cancer.